Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.80 |
| ▸ | RAB9A | P51151 | 6/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.80 |
| ▸ | LMNA | P02545 | 5/20 | 0.80 |
| ▸ | NPC1 | O15118 | 5/20 | 0.80 |
| ▸ | MAPT | P10636 | 2/20 | 0.80 |
| ▸ | TP53 | P04637 | 1/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.79 |
| ▸ | MEN1 | O00255 | 4/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.74 |
| ▸ | CTSV | O60911 | 1/20 | 0.59 |
| ▸ | CTSL | P07711 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2799465 | 0.89 | HPGD (1.00) | HPGDKDM4ERAB9ASMN1; SMN2LMNA | |
| SCHEMBL2799908 | 0.86 | HPGD (0.76) | HPGDKDM4ERAB9ASMN1; SMN2LMNA | |
| SCHEMBL25911109 | 0.85 | MAPT (0.60) | HPGDKDM4ERAB9ASMN1; SMN2LMNA | |
| SCHEMBL18294606 | 0.79 | — | — | |
| SCHEMBL6688057 | 0.78 | HPGD (1.00) | HPGDKDM4ERAB9ASMN1; SMN2LMNA | |
| SCHEMBL7921815 | 0.77 | — | — | |
| SCHEMBL30935699 | 0.76 | HPGD (0.77) | HPGDKDM4ERAB9ASMN1; SMN2LMNA | |
| SCHEMBL6295907 | 0.75 | ALDH1A1 (0.81) | HPGDKDM4ERAB9ASMN1; SMN2LMNA | |
| SCHEMBL6295964 | 0.75 | ALDH1A1 (0.81) | HPGDKDM4ESMN1; SMN2LMNAMAPT | |
| SCHEMBL31237652 | 0.75 | ALDH1A1 (0.82) | HPGDKDM4ERAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168064-A1 | NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS | CHINA MEDICAL UNIVERSITY (TW) | 2010-07-01 | — | — | US | disclosed |
| US-20100168064-A1 | NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS | CHINA MEDICAL UNIVERSITY (TW) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168064-A1 | NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS | DHX30, SLC20A2, DDX20 | HPGD 1886/4885KDM4E 2310/4885RAB9A 2682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.